Susan highlights the significant hurdles in transforming tough tech from lab discoveries to market-ready products, citing the lengthy journey of Herceptin as a prime example. She emphasizes the need for long-term investments and a shift in national policies to foster industrial productivity. The current financial incentives do not support the patience required for developing groundbreaking technologies, which is crucial for building a robust manufacturing base in the U.S.
